Trial Profile
Depressor and anti-inflammatory effects of angiotensin II receptor blockers in metabolic and/or hypertensive patients with coronary artery disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Aug 2016
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary) ; Olmesartan medoxomil
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms DIAMOND study
- 24 Mar 2016 Status changed from recruiting to completed.
- 25 Feb 2015 Planned number of patients changed from 100 to 40 as per University Hospital Medical Information Network - Japan.
- 20 Jan 2015 New trial record